Peer review reports
From: Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China
Original Submission | ||
---|---|---|
6 Sep 2017 | Submitted | Original manuscript |
25 Sep 2017 | Reviewed | Reviewer Report - Samuel Kerk |
30 Oct 2017 | Author responded | Author comments - Lu Xie |
Resubmission - Version 2 | ||
30 Oct 2017 | Submitted | Manuscript version 2 |
28 Dec 2017 | Reviewed | Reviewer Report - Stephen Weiss Lab |
21 Jan 2018 | Author responded | Author comments - Lu Xie |
Resubmission - Version 3 | ||
21 Jan 2018 | Submitted | Manuscript version 3 |
19 Mar 2018 | Author responded | Author comments - Lu Xie |
Resubmission - Version 4 | ||
19 Mar 2018 | Submitted | Manuscript version 4 |
22 Mar 2018 | Author responded | Author comments - Lu Xie |
Resubmission - Version 5 | ||
22 Mar 2018 | Submitted | Manuscript version 5 |
Publishing | ||
26 Mar 2018 | Editorially accepted | |
6 Apr 2018 | Article published | 10.1186/s12885-018-4303-z |